BioSpace News Archive

MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been adjourned to January 5, 2023, at 9:00 a.m. Pacific Time.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency

Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today held its Research and Development Day to provide an extensive overview of the Company’s unique viral immunotherapy platforms and to review updated clinical data from its oncology-focused pipeline.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering.

Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics’ Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. (“Lakeshore”) (Nasdaq: LAAA), a publicly traded special purpose acquisition company.

Cuidalas is a Cure Latam project that was born with the vision of improving the well-being and health of Colombian women, contributing to the early detection of breast cancer thanks to iBreastExam (iBE) certified technology, knowing awareness of social responsibility that each person has to take care of the health of their loved ones and also their own.

Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan.

Emulate, Inc. today announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%.

Novian Health has received Frost & Sullivan’s 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase® Breast Therapy system.